Antidiabetic effect of glucosaminic acid-cobalt (II) chelate in streptozotocin-induced diabetes in mice

• Main Authors: Talba T, Shui XW, Cheng QY, Tian X
• Format: Article
• Language: English
• Published: Dove Medical Press 2011-04-01
• Series: Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
• Online Access: http://www.dovepress.com/antidiabetic-effect-of-glucosaminic-acid-cobalt-ii-chelate-in-streptoz-a7127

Tahirou Talba1, Xia Wen Shui1, Qinyuan Cheng1,2, Xin Tian21Key Laboratory of Food Processing Technology, 2School of Medicine and Pharmaceutics, Jiangnan University, Wuxi, Jiangsu, People's Republic of ChinaBackground: The purpose of this study was to assess the in vivo ability of glucosaminic acid-cobalt (II) chelate to reduce glycemia.Methods: Different concentrations of chelate solution were administrated to mice with diabetes induced by streptozotocin. Daily oral administration of chelate solution 0.4 mL at various concentrations (0.32–0.4 g/mL) led to reduction in water intake by the diabetic mice after 5 days of treatment, with a subsequent reduction in glucose levels observed 2 weeks later. Daily food intake was related to both chelate concentration as well as glycemia reduction. The food intake of mice treated with glucosaminic acid-cobalt (II) chelate solution was 1.5-fold that of untreated mice.Keywords: glucosaminic acid, cobalt, chelate, streptozotocin, glycemia reduction